Martine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $259.70, for a total transaction of $934,920.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at $33,761. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

United Therapeutics Stock Performance

UTHR opened at $266.05 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.64 and a current ratio of 3.77. The stock has a market capitalization of $11.80 billion, a price-to-earnings ratio of 12.58 and a beta of 0.54. The company has a fifty day moving average of $239.87 and a 200 day moving average of $230.35. United Therapeutics Co. has a fifty-two week low of $204.44 and a fifty-two week high of $268.21.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.63 by $0.54. The firm had revenue of $677.70 million for the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The business’s revenue was up 33.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.86 earnings per share. As a group, sell-side analysts forecast that United Therapeutics Co. will post 23.88 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on UTHR shares. The Goldman Sachs Group raised their target price on United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Leerink Partnrs restated an “outperform” rating on shares of United Therapeutics in a research note on Monday, February 5th. HC Wainwright reiterated a “buy” rating and issued a $300.00 price target on shares of United Therapeutics in a research report on Thursday, May 2nd. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research report on Thursday, March 7th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $308.00 target price on shares of United Therapeutics in a report on Thursday, February 22nd. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $308.78.

Institutional Investors Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of United Therapeutics by 19.0% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock worth $5,901,000 after acquiring an additional 4,100 shares during the last quarter. State Board of Administration of Florida Retirement System grew its stake in United Therapeutics by 2.6% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 48,197 shares of the biotechnology company’s stock worth $10,794,000 after acquiring an additional 1,200 shares in the last quarter. ProShare Advisors LLC raised its stake in shares of United Therapeutics by 2.1% during the first quarter. ProShare Advisors LLC now owns 5,589 shares of the biotechnology company’s stock valued at $1,284,000 after acquiring an additional 117 shares in the last quarter. Headlands Technologies LLC boosted its holdings in shares of United Therapeutics by 53.7% in the first quarter. Headlands Technologies LLC now owns 1,131 shares of the biotechnology company’s stock valued at $260,000 after purchasing an additional 395 shares during the period. Finally, Inspire Investing LLC grew its stake in United Therapeutics by 17.6% in the first quarter. Inspire Investing LLC now owns 7,280 shares of the biotechnology company’s stock worth $1,672,000 after purchasing an additional 1,092 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.